Alcon launches CyPass Micro-Stent device for glaucoma surgery

Alcon has announced the European launch of CyPass Micro-Stent, a micro invasive glaucoma surgical device for the treatment of patients with primary open-angle glaucoma.

The device is specifically indicated for the treatment of patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery, or as a standalone procedure in patients who have failed previous medical treatments.

Designed to significantly reduce intraocular pressure, the device is less invasive than traditional glaucoma surgery and is implanted just below the surface of the eye. It leverages the supraciliary space as a new outflow pathway for excess aqueous fluid in the eye.

The CyPass Micro-Stent creates a space between the sclera, the white outer layer of the eyeball and the ciliary body, providing a permanent conduit to improve the eye's natural drainage pathway.

Ian Bell, Alcon's regional president for Europe, the Middle East and Africa, said: "The CyPass Micro-Stent is designed to address the greatest unmet need in glaucoma treatment, reducing patient burden by lowering dependence on topical glaucoma medicine."

It will be made available to patients in the UK, Germany, Italy and Spain, following a successful debut in the US last October. Alcon plans to train and certify more than 500 surgeons in the use of the device in 2017.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.